Supernus Pharmaceuticals (SUPN) said Monday the waiting period for the acquisition of Sage Therapeutics (SAGE) under the US Hart-Scott-Rodino Antitrust Improvements Act expired Friday.
The expiration satisfies one of the conditions for the completion of Supernus' tender offer to acquire all outstanding shares of Sage, the company said.
The tender offer is set to expire at midnight Thursday unless it is extended or terminated earlier, Supernus said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments